AbbVie Strikes Deal With DISCO Worth Up to $2.54 Billion for Cancer Treatments
Key Facts
DISCO Pharmaceuticals announced a collaboration and licensing option agreement with AbbVie on November 19, 2026, with a potential value of up to $2.54 billion, to develop bispecific therapies for solid tumors, according to Reuters. The terms include an upfront payment of $40 million to DISCO, as well as option, development and milestone payments that could reach $2.5 billion, and tiered royalties on global sales. The maximum value is not guaranteed consideration, as a large portion depends on development options and milestones. The agreement gives AbbVie a path to secure exclusive rights to programs it selects after DISCO completes specified research activities. The deal comes as the company seeks to expand its presence in bispecific cancer treatments.
The therapeutic approach relies on designing antibodies that recognize cancer cells when two target proteins are present together, which may reduce damage to healthy tissue, according to Reuters. DISCO describes the approach as "AND-gated," meaning recognition requires both protein signals to be present in the cell. The technology makes targeting conditional on that combination, rather than recognizing a single marker alone. The companies' collaboration focuses on solid tumor treatments, while DISCO has not disclosed how many programs could be covered by the agreement. The company has also not set a date for any program to enter clinical development, leaving the scope of the work and the development timeline unresolved at this stage.
DISCO will conduct the research and discovery work, while AbbVie has the right to exclusively license selected programs for further development after the specified research activities are completed, according to Reuters. The German company said it had not disclosed how many programs could be covered by the agreement. The licensing option also becomes available only after that research is complete, making AbbVie's decision on whether to proceed to development a later step. The report described the agreement as being at a "very early stage," indicating that the programs have not yet reached a publicly announced clinical stage. DISCO's chief executive said the company is targeting the selection of a development candidate in the second half of 2027.
DISCO had been working on "AND-gated" treatments for small cell lung cancer and colorectal cancer, according to Reuters. The agreement comes amid growing interest from major drugmakers in bispecific antibodies, including Bristol Myers Squibb, Pfizer and Merck, the report said. In January 2026, AbbVie had paid RemeGen $650 million upfront for rights outside China to a bispecific drug targeting solid tumors. The new agreement reflects AbbVie's continued push to build treatment options in this field through external partnerships. The DISCO deal has a different structure, relying on research and program selection before an exclusive license becomes available.
AbbVie's global oncology portfolio revenue was $1.696 billion in the third quarter of 2026, up 0.8% on a reported basis compared with the same period a year earlier, according to the company's results. On October 30, the chief executive said AbbVie had strengthened its long-term growth potential through differentiated clinical data and the completion of its acquisition of Apogee Therapeutics. In its quarterly results, the company included clinical data on ABBV-1480, a program developed in partnership with RemeGen, among its presentations on lung cancer in 2026. DISCO said the collaboration will combine the DISCOtech platform for mapping cell-surface proteins with AbbVie's expertise in oncology research and development. AbbVie's shares closed at $286.01 on November 18, compared with $292.82 in the previous session, according to EL7 data; both closes preceded the announcement of the agreement published on November 19.